What is the status of the PCSK9 patent case (updated)?

Amgen’s ($AMGN) patent fight against Regeneron ($REGN) and Sanofi has been quiet for much of this year. But it is likely to heat up again shortly. What is coming up?

Markman AdvisorsOctober 11, 2018Amgen, AMGN, Regeneron, REGN, Sanofi, PCSK9, Praluent, Repatha, patent, invalidity, written description, enablement, injunction, damages, willful infringement, Zachary Silbersher, Silb, SilbersherComment

Blog